N³-benzyl-5-nitrobenzimidazole | 27978-94-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: N³-benzyl-5-nitrobenzimidazole
• 英文别名: 3-benzyl-5-nitro-3H-benzimidazole；1-Benzyl-5-nitrobenzimidazol；1-benzyl-6-nitro-1H-benzoimidazole；1-Benzyl-6-nitrobenzimidazole
• CAS: 27978-94-5
• 化学式: C₁₄H₁₁N₃O₂
• 分子量: 253.26
• InChiKey: NYVRAJAMKRKVSA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  二氟溴乙酸乙酯 、 N³-benzyl-5-nitrobenzimidazole 在 rongalite 、 sulfur 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 24.0h， 以68%的产率得到3-benzyl-1-(difluoromethyl)-5-nitro-1,3-dihydro-2H-benzo[d]imidazole-2-thione
  参考文献：
  名称：

  亚唑与溴二氟乙酸酯和元素硫的反应通过亚硫酸盐促进的N-二氟甲基硫脲的合成

  摘要：

  已经开发了通过N-二氟甲基化和硫化作用的亚硫酸盐促进的唑转化为N-二氟甲基硫脲。在该反应中，廉价的溴二氟乙酸乙酯和无毒的元素硫分别用作二氟甲基化和硫化试剂。各种苯并咪唑，包括苯并咪唑，咪唑和三唑，表现良好，以中等至良好的收率提供了多种吡咯硫脲。

  DOI：

  10.1021/acs.orglett.8b03876
• 作为产物：
  描述：

  氯化苄 、 1-苄基-5-硝基-1H-1,3-苯并咪唑 以 N,N-二甲基甲酰胺 为溶剂， 反应 57.0h， 生成 N³-benzyl-5-nitrobenzimidazole
  参考文献：
  名称：

  Howell, John R.; Rasmussen, Malcolm, Australian Journal of Chemistry, 1993, vol. 46, # 8, p. 1177 - 1191

  摘要：

  DOI：

文献信息

• Novel benzimidazole derivatives
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20030181730A1

  公开（公告）日：2003-09-25

  This invention provides compounds having the structure: 1 wherein each of R 1 , R 2 , R 3 and R 9 is independently H; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or cycloalkenyl; acyl, phenyl, substituted phenyl, or heteroaryl; wherein each dashed line represents a single bond or a double bond with the proviso that if R 1 is present, R 3 is absent and there is a double bond between N at position 3 and C at position 2 and a single bond between C at position 2 and N at position 1 and if R 3 is present, R 1 is absent and there is a double bond between N at position 1 and C at position 2 and a single bond between C at position 2 and N at position 3; wherein each of R 4 , R 5 and R 6 is independently H, F, Cl, Br, I; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; C 3 -C 7 cycloalkyl or cycloalkenyl; phenyl, substituted phenyl, heteroaryl, —OH, —OR 7 , —CN, —COR 7 , —CO 2 R 7 , —CON(R 7 ) 2 , —OCOR 7 , —SR 7 , —N(R 7 ) 2 , —NR 7 COR 7 , —(CH 2 ) n OR 7 , —(CH 2 ) n N(R 7 ) 2 , —(CH 2 ) n NR 7 COR 7 , wherein n is an integer from 1 to 4; and wherein each of R 7 and R 8 is independently H; straight chain or branched, substituted or unsubstituted C 1 -C 7 alkyl, C 2 -C 7 alkenyl or alkynyl; phenyl or substituted phenyl. These compounds are selective for cloned human alpha 2 receptors and are useful as analgesic, sedative or anaesthetic agents.

  本发明提供具有结构的化合物：1其中R1，R2，R3和R9中的每一个都是独立的H; 直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基; C3-C7环烷基或环烯基; 酰基，苯基，取代苯基或杂环基; 其中每个虚线代表单键或双键，前提是如果R1存在，则R3不存在，并且在位置3处的N和位置2处的C之间有双键，在位置2处的C和位置1处的N之间有单键，如果R3存在，则R1不存在，并且在位置1处的N和位置2处的C之间有双键，在位置2处的C和位置3处的N之间有单键; 其中R4，R5和R6中的每一个都是独立的H，F，Cl，Br，I; 直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基; C3-C7环烷基或环烯基; 苯基，取代苯基，杂环基，—OH，—OR7，—CN，—COR7，—CO2R7，—CON(R7)2，—OCOR7，—SR7，—N(R7)2，—NR7COR7，—(CH2)nOR7，—(CH2)nN(R7)2，—(CH2)nNR7COR7，其中n是1到4的整数; 其中R7和R8中的每一个都是独立的H; 直链或支链，取代或未取代的C1-C7烷基，C2-C7烯基或炔基; 苯基或取代苯基。 这些化合物对克隆的人类α2受体具有选择性，并可用作镇痛，镇静或麻醉剂。
• NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY
  申请人：ASAHI KASEI KABUSHIKI KAISHA

  公开号：EP3467930A1

  公开（公告）日：2019-04-10

  The purpose of the present invention is to provide a nonaqueous electrolyte that contains acetonitrile having an excellent balance between viscosity and the dielectric constant and a fluorine-containing inorganic lithium salt, wherein the generation of complex cations comprising a transition metal and acetonitrile is suppressed, excellent load characteristics are exhibited, and increases in internal resistance upon repeated charge/discharge cycles are suppressed; a further purpose of the present invention is to provide a nonaqueous secondary battery. The present invention relates to a nonaqueous electrolyte which contains: a nonaqueous solvent comprising acetonitrile; a fluorine-containing inorganic lithium salt; and a specific nitrogenous cyclic compound typified by benzotriazole.

  本发明的目的是提供一种非水电解液，该电解液含有在粘度和介电常数之间具有极佳平衡的乙腈和含氟无机锂盐，其中包含过渡金属和乙腈的复合阳离子的生成受到抑制，显示出极佳的负载特性，并且在重复充放电循环中内阻的增加受到抑制；本发明的另一个目的是提供一种非水二次电池。本发明涉及一种非水电解液，其中包含：由乙腈组成的非水溶剂；含氟无机锂盐；以及以苯并三唑为典型代表的特定含氮环状化合物。
• N-1H-Benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists
  作者：Cindy Benod、Guy Subra、Virginie Nahoum、Aude Mallavialle、Jean-François Guichou、Julien Milhau、Samuel Roblés、William Bourguet、Jean-Marc Pascussi、Patrick Balaguer

  DOI：10.1016/j.bmc.2008.02.020

  日期：2008.4.1

  The Human Pregnane X Receptor (hPXR) is a nuclear receptor that regulates the expression of phase I and phase II drug-metabolizing enzymes, as well as that of drug transporters. Because this receptor plays a critical role in protecting tissues from potentially toxic endo-and xenobiotics, highly active agonists could represent novel therapeutic tools in treating several human diseases. Using an in vitro screening reporter system that allow to characterize hPXR activators and a first step of chemical modifications of an original agonist ligand (C2BA-4, 1-(2-chlorophenyl)-N-[1-(1-phenylethyl)-1H-benzimidazol-5-yl] methanesulfonamide), we identified compounds with a N-1H-benzimidazol-5-ylbenzenesulfonamide scaffold as a potent family of hPXR agonists. Further chemical modi. cations allowed us to identify enhanced activators, notably N-(1-benzyl-1H-benzimidazol-5-yl)-2,3,4,5,6-pentamethylbenzenesulfonamide (6n) with an EC50 value in the subnanomolar range. Accordingly to their potent EC50, these compounds induced an efficient protection of hPXR against proteolytic digestion by trypsin even at very low ligand concentrations and were able to induce the expression of the main target genes of hPXR, CYP3A4 and CYP2B6, in primary cultures of human hepatocytes. (C) 2008 Elsevier Ltd. All rights reserved.
• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：SYNAPTIC PHARMACEUTICAL CORPORATION

  公开号：EP0775134A1

  公开（公告）日：1997-05-28
• EP0775134A4
  申请人：——

  公开号：EP0775134A4

  公开（公告）日：1997-08-13